The revolutionary anti-obesity drugs semaglutide and tirzepatide have shown promising results in clinical trials, with substantial weight loss outcomes and additional health benefits like reduced risk of severe cardiovascular problems. However, their potential side effects are drawing attention as their usage becomes more widespread. Concerns include gastrointestinal issues such as pancreatitis and gastroparesis and a possible association with muscle mass loss.